Aethlon Medical(US:AEMD) Prnewswire·2024-10-08 12:01Core Insights - Aethlon Medical, Inc. is participating in the 2024 Maxim Healthcare Virtual Summit, with CEO James Frakes scheduled for a fireside chat on October 15, 2024 [1] Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections, as well as applications in organ transplantation [2] - The Hemopurifier has shown efficacy in human studies for removing life-threatening viruses and in pre-clinical studies for eliminating harmful exosomes from biological fluids, utilizing proprietary lectin-based technology [2] - The device is designated as a Breakthrough Device by the FDA for treating advanced or metastatic cancer patients who are unresponsive or intolerant to standard therapies, and for addressing life-threatening viruses lacking approved treatments [2]